Presented by Yelena Y. Janjigian at ASCO 2025, the Phase 3 MATTERHORN study demonstrated that adding durvalumab to FLOT significantly improved event-free survival compared with FLOT alone in patients with resectable gastric and gastroesophageal junction adenocarcinoma, with consistent benefit across subgroups and no new safety concerns.
Presented by Dr. Cesar Perez, this first-in-human phase 1 study of BG-C9074—a B7-H4–targeting antibody-drug conjugate—demonstrated early antitumor activity and a manageable safety profile in heavily pretreated patients with advanced solid tumors.
Martin Dietrich, MD, live from the 2025 ASCO Annual Meeting, presents interim results from the phase 1b DAREONTM-9 study, showing that obrixtamig combined with topotecan is well tolerated and demonstrates promising preliminary efficacy in patients with relapsed or refractory small cell lung cancer, with a confirmed overall response rate of 69%.
Xavier Leleu, MD, PhD, presents primary results from the Phase 3 IRAKLIA study demonstrating noninferior efficacy and a favorable safety profile of subcutaneous versus intravenous isatuximab, both combined with pomalidomide and dexamethasone, in patients with relapsed/refractory multiple myeloma.
Alexander Olawaiye, MD, presents results from the phase 3 ROSELLA trial, in which relacorilant combined with nab-paclitaxel significantly improved progression-free and overall survival vs nab-paclitaxel alone in patients with platinum-resistant ovarian cancer, with a manageable safety profile.
Jaume Capdevila, MD, PhD, presents results from a phase 1 study showing that obrixtamig monotherapy achieves a 40% response rate and durable disease control with manageable safety in patients with extrapulmonary neuroendocrine carcinoma, particularly those with high DLL3 expression.
Mazyar Shadman, MD, MPH, presents data from a matching adjusted indirect comparison (MAIC) of the efficacy of zanubrutinib versus acalabrutinib in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) based on data from the Phase 3 ALPINE and Phase 3 ASCEND trials.
Presented by Amer Zeidan, MBBS, this OncLive Rapid Readout highlights results from the phase 2 ASCERTAIN-V trial, in which an all-oral regimen of decitabine-cedazuridine plus venetoclax achieved a 46.5% complete response rate and a median overall survival of 15.5 months in newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.
Sarah Sammons, MD, presents updated results from the ReDiscover trial at the 2025 ASCO Annual Meeting in Chicago, demonstrating that the mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant shows promising clinical activity and a manageable safety profile in patients with PIK3CA-mutant HR+/HER2– advanced breast cancer.
Sara Tolaney, MD, MPH, presents results from the phase 3 DESTINY-Breast09 study showing that trastuzumab deruxtecan plus pertuzumab improved progression-free survival vs taxane, trastuzumab and pertuzumab (THP) as a first-line treatment in patients with HER2 positive metastatic breast cancer.
Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, presents updated SEQUOIA Arm D results demonstrating deep, durable responses and favorable safety with fixed-duration zanubrutinib plus venetoclax in treatment-naive CLL/SLL, including patients with del(17p)/TP53 mutations.
Dr. Lakshmi Nayak presents results from the Phase II PROSPECT study, demonstrating that tirabrutinib monotherapy yields a 66.7% overall response rate and a manageable safety profile in patients with relapsed or refractory primary central nervous system lymphoma, supporting its potential as an effective treatment option in this challenging population.
Mazyar Shadman, MD, MPH, presents a network meta-analysis evaluating Bruton tyrosine kinase (BTK) inhibitors in high-risk relapsed/refractory CLL, showing that zanubrutinib demonstrated the greatest efficacy in reducing progression and death compared with other BTK inhibitors and treatments.
Dr. Constantine S. Tam presents 5-year follow-up results from the SEQUOIA trial, showing that frontline zanubrutinib provides durable progression-free and overall survival with a consistent safety profile in patients with treatment-naïve CLL/SLL, including those with del(17p). Funding supported by BeOne Medicines USA, Inc. Content independently developed by OncLive.
Jacob Sands, MD, presents promising early-phase trial results for obrixtamig, a novel DLL3-targeting T-cell engager, in patients with large cell neuroendocrine carcinoma of the lung (LCNEC-L), shared at ESMO Congress 2024.
Dr. Kathryn C. Arbour presents preliminary findings from a Phase 1 study showing that zoldonrasib, a selective RAS(ON) G12D inhibitor, demonstrates encouraging antitumor activity and a manageable safety profile in patients with previously treated KRAS G12D–mutant non–small cell lung cancer.
Dr. Jorge E. Cortes presents updated week 96 results from the Phase 3 ASC4FIRST study, showing that asciminib continues to demonstrate superior efficacy and a more favorable safety profile compared with investigator-selected TKIs in newly diagnosed chronic-phase CML, reinforcing its potential as a standard of care.
Dr. Debra Richardson presents a subgroup analysis of the SIENDO trial, showing that selinexor maintenance therapy significantly improves progression-free survival and delays subsequent treatment in patients with TP53 wild-type advanced or recurrent endometrial cancer, with manageable safety and potential long-term benefit.
Dr. Aaron Gerds presents results from the Phase 2 ACE-536-MF-001 study, demonstrating that luspatercept improves anemia in patients with myelofibrosis—with or without transfusion dependence—and shows encouraging activity when combined with ruxolitinib, with a manageable safety profile and no new safety signals.
Suresh S. Ramalingam, MD, FACP, FASCO, presents updated overall survival data from the Phase 3 LAURA study, demonstrating that osimertinib after chemoradiotherapy provides clinically meaningful progression-free survival benefits and favorable survival trends in patients with unresectable stage III EGFR-mutated NSCLC.
Dr. Benjamin Weinberg presents findings from a ctDNA-based analysis of the CALGB/SWOG 80702 trial, showing that circulating tumor DNA status may help identify patients with stage III colon cancer who could benefit from celecoxib added to standard adjuvant chemotherapy, offering a potential biomarker-driven approach to personalized treatment.
Dr. Robert E. Schoen presents findings from the α-CORRECT study, highlighting the potential of circulating tumor DNA (ctDNA) as a biomarker for recurrence risk assessment in patients with stage III colorectal cancer.
Dr. Catherine Lee presents a post-hoc analysis of the AGAVE-201 trial, demonstrating that axatilimab achieves consistent overall response rates in patients with chronic graft-versus-host disease regardless of prior lines of therapy, with rapid and durable responses, particularly following ruxolitinib, and a favorable safety profile.
Dr. Fred Saad presents a post-hoc analysis of the Phase 3 ARANOTE trial, demonstrating that darolutamide plus androgen-deprivation therapy significantly improves radiographic progression-free survival and delays metastatic castration-resistant prostate cancer in patients with metastatic hormone-sensitive prostate cancer, with consistent efficacy across disease volume subgroups and a favorable safety profile.
Dr. Eric Singhi presents preliminary findings from the Phase I/II SOHO-01 trial, demonstrating that the oral HER2-targeted tyrosine kinase inhibitor BAY 2927088 achieves high response rates and durable disease control in patients with pretreated HER2-mutant NSCLC, with a manageable safety profile.
Marina Konopleva, MD, presents a subanalysis of a pivotal trial evaluating tagraxofusp in treatment-naïve BPDCN, demonstrating its potent anti-tumor activity, rapid clearance of peripheral blasts, and restoration of normal hematopoiesis without cumulative myelosuppression.
Dr. Heinz-Josef Lenz presents first results from the CheckMate 8HW trial, demonstrating that nivolumab plus ipilimumab significantly improves progression-free survival and overall response rates compared to nivolumab monotherapy in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer across all lines of therapy.
Dr. Constantine S. Tam presents preliminary results from the Phase 1 CaDAnCe-101 study, highlighting the promising efficacy and safety of the BTK degrader BGB-16673 in heavily pretreated patients with relapsed or refractory CLL/SLL, including those with BTK inhibitor resistance and Richter transformation.
Dr. Wojciech Jurczak presents first disclosure results from the EPCORE DLBCL-3 trial, demonstrating that fixed-duration subcutaneous epcoritamab monotherapy achieves high response rates with a manageable safety profile in older, anthracycline-ineligible patients with previously untreated large B-cell lymphoma.
Dr. Elias K. Mai presents final progression-free survival results from the Phase 3 GMMG-HD7 trial, demonstrating that adding isatuximab to lenalidomide, bortezomib, and dexamethasone (Isa-RVd) significantly improves minimal residual disease negativity and reduces the risk of progression or death in transplant-eligible patients with newly diagnosed multiple myeloma.
